EMA finds lack of evidence on pancreatic risks with GLP-1s

Current evidence does not show that glucagon-like peptide-1 agonists increase the risk of pancreatitis and pancreatic-duct metaplasia in patients with type 2 diabetes, the European Medicines Agency's Committee for Medicinal Products for Human Use indicated. "However, the number of events is too small to draw final conclusions. Due to their mechanism of action, some uncertainties remain in respect to the long-term effect of these medicines on the pancreas, and more data collection efforts are under way," the agency stated.

View Full Article in:

Healio · New York Times (tiered subscription model), The · PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI